TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.

Sara M Tolaney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.